Monday, November 14^th:

12:55 pm – 1:55 pm PST

Larry Pitcher,
Senior Director and General Manager,
Microbial Manufacturing Services, mRNA, Advanced Therapies

Strategies for navigating CDMOs as a small biotech and the value of early engagement

 

About Larry Pitcher
Operations and business leader with experience running manufacturing sites across different geographies and regulated industries. Currently, Larry is serving as the GM for Thermo Fisher’s rapidly growing Plasmid DNA CDMO business with multi-site responsibilities. Previously, he has held GM roles for Thermo Fisher’s viral vector manufacturing CDMO business at both the Alachua, FL and Cambridge, MA locations.

Before joining the CGT industry with Thermo Fisher Scientific, via Brammer Bio, Larry spent over a decade with RTI Surgical in the Medical Device, HCTP, and pharmaceutical space leading sites in Europe and the US. Larry holds a B.S. in Engineering and MBA.

Monday, November 14^th:

11:40 am PST, Room 1.

Joao Paulo Mattos,
Director,
Global Process Validation and CMC lead,
Biologics

Pushing the efficient frontier of biomanufacturing to speed up drug development and enhance productivity

 

About Joao Paulo Mattos
Joao Paulo Mattos is Director of Global Process Validation and CMC Lead at Thermo Fisher Scientific and has responsibility for process validation and CMC strategy for late stage and commercial programs across six drug substance manufacturing and development sites located globally.

Joao Paulo has previously held roles in manufacturing sciences, process validation, and technology transfer. Prior to joining Thermo Fisher Joao Paulo worked for Bluebird bio, TESARO, and Bristol-Myers Squibb. He holds a B.S. in Chemical-Biological Engineering from MIT, and a Ph.D in Bioengineering from Rice University.

Tuesday, November 15^th:

12:55 pm – 1:55 pm PST

Pouria Motevalian,
Director of Process Development

Bringing the Digital Revolution to Gene Therapy Process Development and Scale-Up

 

About Pouria Motevalian
As Director of Process Development, Pouria Motevalian leads process characterization, optimization and scale up for viral vectors at Thermo Fisher Scientific. Additionally, he oversees process modeling/simulation and knowledge management activities. Prior to joining Thermo Fisher Scientific, Pouria led early and late-stage process development of biologics, conjugate/mRNA vaccines, at Pfizer. Furthermore, he played an integral part in deploying new technologies focused on digital enablement in bioprocess research and development.

Pouria received his Ph.D. in Chemical Engineering with minor in Computational Science from the Pennsylvania State University. He has been an active contributor to the professional and scientific community in ACS, AIChE and AAPS.